What If You Could Halt Immune Cell Memory?
JDRF-funded researchers have discovered a protein on immune cells that, when it is disabled, could halt immune cell memory.
How Type 1 Diabetes was Established as an Autoimmune Disease
In 1974, two teams showed that diabetes is associated with antibodies against beta cells, which helped establish T1D as an autoimmune disease.
The Power of the Patient Voice: Breakthrough T1D Video
In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes is almost the only major autoimmune disease now that does not have a licensed immunotherapy.” And he’s going to change that.
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of […]
Public and Private Organizations, All with the Same Goal: End T1D
In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and private entities working together to fund research aimed at biomarker discovery and the prevention of type 1 diabetes (T1D), received an additional €12 million in funding from the European Commission, Breakthrough T1D and the Helmsley […]
Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic
Carla Greenbaum, M.D., chair of TrialNet—an international Breakthrough T1D-supported network that is dedicated to finding cures for type 1 diabetes (T1D)—and a professor at Benaroya Research Institute, discussed T1D research in the time of COVID-19, including what TrialNet is up to, on Breakthrough T1D’s Facebook Live event. She chats about: What do we know now […]
New Research Suggests that T1D Has Two Distinct Types
Breakthrough T1D-funded researchers found that type 1 diabetes is comprised of two different subtypes, called endotypes, which are dependent upon the age at diagnosis.
Why Does One Scientist Seek Cures for T1D? Answer: Family
Reza Abdi, M.D., has a reason to care about type 1 diabetes research—he has a father and a brother with the disease. Dr. Abdi, of Brigham and Women’s Hospital in Boston, is an expert in immune therapy research, specifically nanotechnologies—miniscule therapies that can deliver immune treatments to specific regions in the body. His goal: To […]
Breakthrough T1D Launches First Center of Excellence, Aiming to Accelerate Type 1 Diabetes Research
Breakthrough T1D today launched its first Center of Excellence, a new research and funding model aimed at accelerating leading type one diabetes (T1D) research. The new Breakthrough T1D Northern California Center of Excellence will unite the work being done at Stanford University and the University of California, San Francisco, focusing on beta cell therapies and […]
FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay of type 1 diabetes (T1D) in individuals at-risk of developing the disease. CD3 is a blood marker that helps to activate the immune cells—called T cells—which are thought to be responsible for the […]
